Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In a double-blind, placebo-controlled trial comparing alprazolam and imipramine for panic disorder, serum analysis revealed that a substantial proportion of the patients took explicitly prohibited anxiolytic medication. Excluding these patients changed the results.

Original publication

DOI

10.1176/ajp.147.4.507

Type

Journal article

Journal

Am J Psychiatry

Publication Date

04/1990

Volume

147

Pages

507 - 509

Keywords

Adult, Alprazolam, Anti-Anxiety Agents, Anxiety Disorders, Clinical Trials as Topic, Double-Blind Method, Fear, Female, Humans, Imipramine, Male, Outcome and Process Assessment (Health Care), Panic, Patient Compliance, Placebos, Self Medication